Malik Suliman Mohamed

Dr. Malik Suliman Mohamed

University of Khartoum, Khartoum, Sudan
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
TETilal Elsaman
Tilal Elsaman
MMMalik Suliman Mohamed
Malik Suliman Mohamed
EEEYMAN MOHAMED ELTAYIB
EYMAN MOHAMED ELTAYIB
HAHatem Abdel-Aziz
Hatem Abdel-Aziz
AAAbualgasim Elgaili Abdalla
Abualgasim Elgaili Abdalla
MMMalik Suliman Mohamed
Malik Suliman Mohamed

31 December 2018 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
FAFathi A. Amer
Fathi A. Amer
MMMalik Suliman Mohamed
Malik Suliman Mohamed
AEAbuabker Elbur
Abuabker Elbur
SASulafa I. Abdelaziz
Sulafa I. Abdelaziz
ZEZeinab A. Elrayah
Zeinab A. Elrayah
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

27 August 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LELamis Y. M. Elkheir
Lamis Y. M. Elkheir
RHRayan Haroun
Rayan Haroun
MMMalik Suliman Mohamed
Malik Suliman Mohamed
Ahned FahalAhned Fahal
Ahned Fahal

3 February 2019 in Journal of Chemistry
Verified
Journal Article
Open access
PDF file
MAMazin A. S. Abdelwahid
Mazin A. S. Abdelwahid
TETilal Elsaman
Tilal Elsaman
MMMalik Suliman Mohamed
Malik Suliman Mohamed
SLSara A. Latif
Sara A. Latif
MMMoawia M. Mukhtar
Moawia M. Mukhtar
MMMagdi A. Mohamed
Magdi A. Mohamed
Leishmaniasis is a fatal neglected parasitic disease caused by protozoa of the genusLeishmaniaand transmitted to humans by different species ofphlebotominesandflies. The disease incidence continues to increase due to lack of vaccines and prophylactic drugs. Drugs commonly used for the treatment are frequently toxic and highly expensive. The problem of these drugs is further complicated by the development of resistance. Thus, there is an urgent need to develop new antileishmanial drug candidates. The aim of this study was to synthesize certain quinoline-4-carboxylic acids, confirm their chemical structures, and evaluate their antileishmanial activity. Pfitzinger reaction was employed to synthesize fifteen quinoline-4-carboxylic acids (Q1-Q15) by reacting equimolar mixtures of isatin derivatives and appropriateα-methyl ketone. The products were purified, and their respective chemical structures were deduced using various spectral tools (IR, MS,1H NMR, and13C NMR). Then, they were investigated againstL. donovanipromastigote (clinical isolate) in different concentration levels (200 μg/mL to 1.56 μg/mL) against sodium stibogluconate and amphotericin B as positive controls. The IC50for each compound was determined and manipulated statistically. Among these compounds,Q1(2-methylquinoline-4-carboxylic acid) was found to be the most active in terms of IC50.

30 August 2022 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
AMAhmed Osman Mohamed
Ahmed Osman Mohamed
MMMalik Suliman Mohamed
Malik Suliman Mohamed
Tauqeer Hussain MallhiTauqeer Hussain Mallhi
Tauqeer Hussain Mallhi
MHMohamed Hussain
Mohamed Hussain
MJMohammad Ali Jalloh
Mohammad Ali Jalloh
Alaa’Aldeen MakkiAlaa’Aldeen Makki
Alaa’Aldeen Makki
Introduction: Vulvovaginal candidiasis (VVC) is a yeast infection of the vulva, which is caused by Candida species and affects women worldwide. Pregnant women are more vulnerable to VVC due to certain risks. Moreover, their offspring are also exposed to the risk of preterm birth. In this context, ascertaining the burden of VVC is of paramount importance and this meta-analysis was conducted to estimate the occurrence of VVC among pregnant women in Africa. Methodology: Database search was carried out through PubMed, Scopus, Science-Direct, and Google Scholar from the date of inception until December 2020. All the studies on the prevalence of VVC among African pregnant women were included in the analysis. The pooled prevalence was estimated based on the Random-effect model DerSimonian-Laird approach with Freeman- Tukey double arcsine transformed proportion. Heterogeneity was assessed using I2 test and subsequently explored using subgroup and meta-regression analysis. Results: A total of Sixteen records having a sample size 4,185 were included in this study. The overall prevalence of VVC was pooled at 29.2% (CI 95%: 23.4 – 33.0). Subgroup analysis revealed a higher prevalence in Eastern Africa, followed by Western Africa and North Africa (35%, 28%, and 15% respectively). Moderator analysis indicated that the studies that used advanced methods of detection had a higher prevalence (p = 0.048). In addition, the large sample size was associated with higher prevalence (p ≤ 0.001). No other moderators were found to be statistically significant. Conclusions: The overall prevalence of VVC among African pregnant women is comparable to other studies worldwide. However, appropriate identification techniques and larger sample size could likely be associated with an increased prevalence. Our findings necessitate the need for further investigations to determine the geographical distribution of VVC across African regions.

4 November 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Muhammad SalmanMuhammad Salman
Muhammad Salman
Tauqeer Hussain MallhiTauqeer Hussain Mallhi
Tauqeer Hussain Mallhi
NTNida Tanveer
Nida Tanveer
NSNaureen Shehzadi
Naureen Shehzadi
HKHumaira Majeed Khan
Humaira Majeed Khan
Yusra Habib KhanYusra Habib Khan
Yusra Habib Khan
Vaccination protects people from serious illness and associated complications. Conspiracy theories and misinformation on vaccines have been rampant during the COVID-19 pandemic and are considered significant drivers of vaccine hesitancy. Since vaccine hesitancy can undermine efforts to immunize the population against COVID-19 and interferes with the vaccination rate, this study aimed to ascertain the COVID-19-vaccine-related conspiracy beliefs, vaccine hesitancy, views regarding vaccine mandates, and willingness to pay for vaccines among the general population. A web-based, cross-sectional survey was conducted (April–August 2021) among the adult population in six countries (Pakistan, Saudi Arabia, India, Malaysia, Sudan, and Egypt). Participants were recruited using an exponential, non-discriminate snowball sampling method. A validated self-completed electronic questionnaire was used for the data collection. All the participants responded to questions on various domains of the study instrument, including conspiracy beliefs, vaccine hesitancy, and willingness to pay. The responses were scored according to predefined criteria and stratified into various groups. All data were entered and analyzed using SPSS version 22. A total of 2481 responses were included in the study (Pakistan 24.1%, Saudi Arabia 19.5%, India 11.6%, Malaysia 8.1%, Sudan 19.3%, and Egypt 17.3%). There was a preponderance of participants ≤40 years old (18–25 years: 55.8%, 26–40 years: 28.5%) and females (57.1%). The average score of the COVID-19 vaccine conspiracy belief scale (C19V-CBS) was 2.30 ± 2.12 (median 2; range 0–7). Our analysis showed that 30% of the respondents were found to achieve the ideal score of zero, indicating no conspiracy belief. The mean score of the COVID-19 vaccine hesitancy scale (C19V-HS) was 25.93 ± 8.11 (range: 10–50). The majority (45.7%) had C19V-HA scores of 21–30 and nearly 28% achieved a score greater than 30, indicating a higher degree of hesitancy. There was a significant positive correlation between conspiracy beliefs and vaccine hesitancy (Spearman’s rho = 0.547, p < 0.001). Half of the study population were against the vaccine mandate. Respondents in favor of governmental enforcement of COVID-19 vaccines had significantly (p < 0.001) lower scores on the C19V-CBS and C19V-HS scale. Nearly 52% reported that they would only take vaccine if it were free, and only 24% were willing to pay for COVID-19 vaccines. A high prevalence of conspiracy beliefs and vaccine hesitancy was observed in the targeted countries. Our findings highlight the dire need for aggressive measures to counter the conspiracy beliefs and factors underlying this vaccine hesitancy.